Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI
Zijian Zhou(The University of Texas MD Anderson Cancer Center), Jingfei Ma(The University of Texas MD Anderson Cancer Center), Marion E. Scoggins(The University of Texas MD Anderson Cancer Center), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Kelly K. Hunt(The University of Texas MD Anderson Cancer Center), Jason B. White(The University of Texas MD Anderson Cancer Center), Rania M. Mohamed(The University of Texas MD Anderson Cancer Center), Gaiane M. Rauch(The University of Texas MD Anderson Cancer Center), Miral Patel(The University of Texas MD Anderson Cancer Center), Bikash Panthi(The University of Texas MD Anderson Cancer Center), Sanaz Pashapoor(The University of Texas MD Anderson Cancer Center), Jong Bum Son(The University of Texas MD Anderson Cancer Center), Mary S. Guirguis(The University of Texas MD Anderson Cancer Center), Jia Sun(Nanjing University of Chinese Medicine), Clinton Yam(The University of Texas MD Anderson Cancer Center), Rosalind P. Candelaria(The University of Texas MD Anderson Cancer Center), Tanya W. Moseley(The University of Texas MD Anderson Cancer Center), Beatriz E. Adrada(The University of Texas MD Anderson Cancer Center), Zhan Xu(The University of Texas MD Anderson Cancer Center), Nabil Elshafeey(The University of Texas MD Anderson Cancer Center), Vicente Valero(The University of Texas MD Anderson Cancer Center), Wei Yang(Shanghai Jiao Tong University), Medine Böge(The University of Texas MD Anderson Cancer Center), Mark D. Pagel(University of Wisconsin–Madison), Gary J. Whitman(The University of Texas MD Anderson Cancer Center), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Peng Wei(Creighton University)
Cited by 44
Related Papers
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k